-- Alkermes, Amylin, Delta Air, US Airways: U.S. Equity Preview
-- B y   N i k o l a j   G a m m e l t o f t
-- 2012-01-27T22:30:58Z
-- http://www.bloomberg.com/news/2012-01-27/alkermes-amylin-delta-air-us-airways-u-s-equity-preview.html
Shares of the following companies
may have unusual moves in U.S. trading on Jan. 30. Stock symbols
are in parentheses, and prices are as of 5 p.m. in New York.  Amylin Pharmaceuticals Inc. (AMLN)   added 15 percent to
$13.92 and  Alkermes Inc. (ALKS)   gained 4.7 percent to $20.
The drugmakers succeeded in their third attempt to gain U.S.
clearance for Bydureon, a once-weekly version of Amylinâ€™s
diabetes shot. The Food and Drug Administration approved the
drug for adults with Type 2 diabetes.  US Airways Group Inc. (LCC)   rose 3.9 percent to $8.50.
 Delta Air Lines Inc. (DAL)   is studying making an offer for
the smallest full-service domestic carrier, the Wall Street
Journal reported, citing people familiar with the matter. US
Airways confirmed earlier this month it is evaluating a possible
merger with American Airlines parent AMR Corp. (AAMRQ US) in
bankruptcy. TPG Capital and Delta also are evaluating possible
bids for American, people familiar with the matter have said.  To contact the reporter on this story:
Nikolaj Gammeltoft in  New York  at 
 ngammeltoft@bloomberg.net   To contact the editor responsible for this story:
Nick Baker at   nbaker7@bloomberg.net . 